Skin disorders, Medicines planning
5 results
Applied filters
The licence and supporting evidence for omalizumab biosimilar
21 January 2026One omalizumab biosimilar is currently available: Omlyco. Learn about the licensed indications, available preparations, supporting evidence and key differences.
Preparing to use omalizumab biosimilar
20 January 2026One omalizumab biosimilar (Omlyclo) is available and other biosimilars are in development. We offer general information and implementation advice.
Preparing to use ustekinumab biosimilar
29 July 2025Introducing biosimilar ustekinumab needs planning. Work with the multidisciplinary team to ensure familiarity with the area and develop an implementation plan.
Good governance when implementing ustekinumab biosimilar
29 July 2025Governance should consider processes for approval, procurement and supply, prescribing and administration, monitoring, and pharmacovigilance.
The licence and supporting evidence for ustekinumab biosimilars
29 July 2025Ustekinumab biosimilars (Pyzchiva, Steqeyma, Uzpruvo, Wezenla) are licensed. Learn about indications, formulations, supporting evidence and differences.